ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,036Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 251

$496K Total Retail Price of All Prescriptions

Rank: 16 out of 251

356 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
68% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

13% of this provider’s 356 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

4% of this provider’s 356 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,403 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
SIMVASTATIN 392 324 1 1
LISINOPRIL 283 228 2 2
METOPROLOL TARTRATE 274 223 3 7
LEVOTHYROXINE SODIUM 271 205 4 3
FUROSEMIDE 262 232 5 6
SERTRALINE HCL 217 196 6 22
AMLODIPINE BESYLATE 184 164 7 4
OMEPRAZOLE 175 127 8 5
METFORMIN HCL 172 119 9 10
ATORVASTATIN CALCIUM 161 134 10 8
MIRTAZAPINE 138 138 11 36
POTASSIUM CHLORIDE 134 111 12 33
GLIPIZIDE 134 109 12 56
CITALOPRAM HBR 118 101 14 15
PRAVASTATIN SODIUM 113 72 15 14
DIOVAN 111 107 16 23
JANUVIA 111 94 16 82
HYDROCHLOROTHIAZIDE 110 110 18 9
ADVAIR DISKUS 108 81 19 25
GABAPENTIN 106 63 20 16
TRAZODONE HCL 104 67 21 26
WARFARIN SODIUM 104 94 21 11
PANTOPRAZOLE SODIUM 100 76 23 20
METOPROLOL SUCCINATE 89 79 24 13
DONEPEZIL HCL 86 85 25 29
TRAMADOL HCL 84 76 26 24
ENALAPRIL MALEATE 80 31 27 61
SPIRIVA 79 53 28 37
CARVEDILOL 72 54 29 41
ALENDRONATE SODIUM 72 72 29 39
DIGOXIN 69 53 31 68
CLOPIDOGREL 68 60 32 60
RANITIDINE HCL 67 43 33 35
CRESTOR 65 54 34 21
KLOR-CON M20 64 63 35 45
GLIMEPIRIDE 63 41 36 62
LOSARTAN POTASSIUM 63 50 36 17
NOVOLOG 62 52 38 71
FENOFIBRATE 62 56 38 126
OXYBUTYNIN CHLORIDE ER 59 20 40 110
PREDNISONE 56 47 41 27
VENLAFAXINE HCL ER 56 48 41 58
OXYCODONE-ACETAMINOPHEN 55 27 S2 43 55
CARBIDOPA-LEVODOPA 53 41 44 67
PLAVIX 52 42 45 100
LEVEMIR 51 39 46 104
ALLOPURINOL 50 50 47 34
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.